Eli Lilly Sets October 29 Date for Third-Quarter 2026 Financial Results
Eli Lilly confirms it will report Q3 2026 financial results on October 29, 2026, followed by a scheduled conference call with the…
Eli Lilly confirms it will report Q3 2026 financial results on October 29, 2026, followed by a scheduled conference call with the…
Eli Lilly's latest clinical data reveals that the combination of Taltz and Zepbound drives significant biomarker improvements in psoriasis patients, reinforcing the…
Eli Lilly shares gain as new clinical data for EBGLYSS confirms long-term efficacy and reduced topical treatment needs for patients suffering from…
Eli Lilly expands its oncology footprint as the FDA approves Jaypirca for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,…
Eli Lilly's oral GLP-1 drug orforglipron demonstrates significant cardiovascular safety and efficacy in phase 3 trials, showing a 16% lower risk of…
Eli Lilly's EloraTZP trial results show a 23.3% average weight loss, signaling a potential new benchmark in the company's obesity and type…
Eli Lilly reports positive Phase 3b results for EBGLYSS, showing significant skin clearance and symptom relief for patients with hand and foot…
Eli Lilly reports positive Phase 3 data for retatrutide, with patients achieving 20.8% weight loss over 80 weeks, strengthening the company's competitive…
Investor sentiment turns bearish on Novo Nordisk while Eli Lilly gains favor amid shifting dynamics in the obesity-drug market.
Eli Lilly-backed biotech Scribe Therapeutics jumps 50% after upsized IPO, signaling renewed biotech IPO momentum.
Scribe Therapeutics, backed by Eli Lilly, raised $128.7 million in an upsized IPO, reflecting strong investor demand for biotech firms with major…
Scribe Therapeutics, with Eli Lilly’s backing, files for a $107.2 million IPO, highlighting gene-editing sector momentum and potential biotech IPO revival.